Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Share-based Compensation: 2013-2025

Historic Share-based Compensation for Ocular Therapeutix (OCUL) over the last 13 years, with Sep 2025 value amounting to $11.7 million.

  • Ocular Therapeutix's Share-based Compensation rose 76.04% to $11.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $39.0 million, marking a year-over-year increase of 29.04%. This contributed to the annual value of $33.1 million for FY2024, which is 85.74% up from last year.
  • As of Q3 2025, Ocular Therapeutix's Share-based Compensation stood at $11.7 million, which was up 20.80% from $9.7 million recorded in Q2 2025.
  • Over the past 5 years, Ocular Therapeutix's Share-based Compensation peaked at $11.7 million during Q3 2025, and registered a low of $3.1 million during Q1 2021.
  • In the last 3 years, Ocular Therapeutix's Share-based Compensation had a median value of $7.2 million in 2024 and averaged $7.5 million.
  • As far as peak fluctuations go, Ocular Therapeutix's Share-based Compensation spiked by 155.90% in 2024, and later fell by 14.30% in 2025.
  • Ocular Therapeutix's Share-based Compensation (Quarterly) stood at $3.8 million in 2021, then rose by 10.20% to $4.2 million in 2022, then grew by 2.22% to $4.3 million in 2023, then surged by 66.29% to $7.2 million in 2024, then surged by 76.04% to $11.7 million in 2025.
  • Its Share-based Compensation was $11.7 million in Q3 2025, compared to $9.7 million in Q2 2025 and $10.5 million in Q1 2025.